V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Grey Cap PDF
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Orange Cap PDF
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Purple Cap PDF
VCP WHO Prequalification of Vector Control Products – Source Material Specification Application Form DOCX
M WHO prequalified quality control laboratory (QCL) annual report on activities (1 October 2016) DOCX
M WHO Procedure for Prequalification of Biotherapeutic Products or their corresponding Similar Biotherapeutic Products PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Grey Cap PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Orange Cap PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Purple Cap PDF
V WHO Product Leaflet for Health Workers - Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELD PDF
V WHO Recommendation for EUL of AZD1222 submitted by AstraZeneca AB and manufactured by SK Bioscience Co Ltd. (Published: 23 February 2021) PDF
VCP WHO specification for source material - New applications and extensions (VCP Advice to manufacturers series) PDF
V WHO Summary of Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Orange Cap PDF
M WHO TRS 1003 Annex 3 - Procedure for assessing the acceptability in principle of quality control laboratories for use by the United Nations agencies PDF